Genetic susceptibility to adverse drug effects - Epidemiology ...
Genetic susceptibility to adverse drug effects - Epidemiology ...
Genetic susceptibility to adverse drug effects - Epidemiology ...
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
4.2<br />
Common NOS1AP variants potentiate digoxin induced<br />
QT-shortening and risk of sudden cardiac death<br />
Abstract<br />
Background. Digoxin, widely used in the treatment of heart failure and atrial fibrillation, is associated<br />
with increased risk of life-threatening arrhythmias. Common variants of the NOS1AP<br />
gene were recently shown <strong>to</strong> be associated with QT-prolongation. We analyzed the combined<br />
effect of NOS1AP genotype and digoxin on QTc-interval duration and the risk of sudden cardiac<br />
death (SCD) <strong>to</strong> digoxin.<br />
Methods. We studied the Rotterdam Study, a population-based, prospective cohort study of<br />
individuals ≥55 years of age. Heart rate corrected QT (QTc) interval duration was measured<br />
in prospectively collected ECGs. Digoxin exposure was determined at the time of each ECG.<br />
Hazard ratios (HRs) for time <strong>to</strong> SCD among NOS1AP genotypes with and without digoxin<br />
were estimated by Cox proportional hazards modeling with time-dependent exposures.<br />
Results. We included 16,595 ECGs from 7771 individuals (315 ECGs from 243 individuals on<br />
digoxin). In digoxin users, NOS1AP minor alleles were associated with increased QTc shortening<br />
of 4.3 msec per additional allele compared <strong>to</strong> subjects homozygous for the reference<br />
allele. There were 229 SCD cases, 40 of whom were exposed <strong>to</strong> digoxin at time of death. In<br />
digoxin users, NOS1AP minor alleles were associated with an increased risk of SCD of 1.78<br />
(95%CI 1.13;2.81) per additional allele, resulting in a 3-fold increased SCD risk for homozygous<br />
minor allele carriers. NOS1AP variants did not increase SCD risk in non-digoxin users.<br />
Conclusions. Minor allele carriers of a common NOS1AP variant using digoxin have exaggerated<br />
QTc shortening and an increased risk of SCD.<br />
89